Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Hikma Pharmaceuticals ( (GB:HIK) ) is now available.
Hikma Pharmaceuticals has reported that senior executives Julie Hill and Sam Park have received ordinary shares following the vesting of conditional awards granted in April 2024 under the company’s 2023 Long-Term Incentive Plan. The transactions, which were executed on 9 April 2026 on the London Stock Exchange, included subsequent share sales at £13.09 per share to cover related tax liabilities, reflecting routine remuneration and alignment of management incentives with shareholder interests.
Under the vesting, Hill acquired 8,188 shares at no cost and sold 3,121 shares to meet tax obligations, while Park received 19,045 shares and disposed of 7,259 shares for the same purpose. The disclosures, made in line with regulatory requirements for persons discharging managerial responsibilities, underscore Hikma’s ongoing use of equity-based incentives as part of its long-term compensation structure for key management.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company listed in London and on Nasdaq Dubai, operating in the generic and specialty medicines sector. The group focuses on developing, manufacturing and marketing a broad range of injectable, oral and inhaled treatments, with a strong presence in the U.K., Middle East and North Africa, and U.S. markets.
Average Trading Volume: 1,397,768
Technical Sentiment Signal: Sell
Current Market Cap: £2.86B
For detailed information about HIK stock, go to TipRanks’ Stock Analysis page.